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Abstract
Objectives—Flat epithelial atypia (FEA) is a relatively new diagnostic term with uncertain 
clinical significance for surgical management. Any implied risk of invasive breast cancer 
associated with FEA is contingent upon diagnostic reproducibility, yet little is known regarding its 
use.
Materials and Methods—Pathologists in the Breast Pathology Study interpreted one of four 
60-case test sets, one slide per case, constructed from 240 breast biopsy specimens. An electronic 
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data form with standardized diagnostic categories was used; participants were instructed to 
indicate all diagnoses present. We assessed participants’ use of FEA as a diagnostic term within: 
1) each test set; 2) 72 cases classified by reference as benign without FEA; and 3) six cases 
classified by reference as FEA. 115 pathologists participated, providing 6,900 total independent 
assessments.
Results—Notation of FEA ranged from 0% to 35% of the cases interpreted, with most 
pathologists noting FEA on 4 or more test cases. At least one participant noted FEA in 34 of the 
72 benign non-FEA cases. For the 6 reference FEA cases, participant agreement with the case 
reference FEA diagnosis ranged from 17% to 52%; diagnoses noted by participating pathologists 
for these FEA cases included columnar cell hyperplasia, usual ductal hyperplasia, atypical lobular 
hyperplasia, and atypical ductal hyperplasia.
Conclusions—We observed wide variation in the diagnosis of FEA among U.S. pathologists. 
This suggests that perceptions of diagnostic criteria and any implied risk associated with FEA may 
also vary. Surgical excision following a core biopsy diagnosis of FEA should be reconsidered and 
studied further.
Keywords
breast oncology; atypia; flat epithelial atypia; biopsy; observer variability
Introduction
Surgeons rely on the pathologist’s interpretation of a biopsy specimen to guide their 
management recommendations for women with abnormalities noted on mammography. This 
can be a difficult discussion, especially when carcinoma or atypia is part of the diagnosis. 
Many women and physicians are concerned about missing a carcinoma following a core 
biopsy diagnosis of atypia. Delay in diagnosis of breast cancer and failure to detect breast 
cancer are leading medical malpractice allegations,1 and may further encourage surgical 
management for atypical breast biopsy findings including flat epithelial atypia (FEA).
Up to 10% of core needle breast biopsies may include FEA, a type of proliferative 
intraductal epithelium associated with breast microcalcifications detected by radiologic 
imaging.2 Each year, 1.6 million breast biopsies are performed on women in the United 
States,3,4 suggesting a large number of women will be diagnosed with FEA. The World 
Health Organization (WHO) established the defining features of FEA in 2003.5 In the most 
recent WHO classification, FEA is defined as “a neoplastic alteration of the terminal-duct 
lobular units (TDLUs) characterized by replacement of the native epithelial cells by one to 
several layers of a single epithelial cell type showing low-grade (monomorphic) cytological 
atypia.”6 This WHO text description is accompanied by photomicrograph examples to assist 
distinguishing FEA from other epithelial proliferations with monomorphic cytological 
atypia.
Although earlier research posited the theory that pure FEA corresponds to a precursor stage 
of ductal carcinoma in situ (DCIS) or invasive carcinoma, most studies have shown that FEA 
rarely progresses to carcinoma.7–12 Nevertheless, a diagnosis of FEA includes the word 
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“atypia” in its name, potentially causing concern to patients and clinicians. FEA has been 
associated with and may coexist with a family of indolent risk-associated proliferative 
lesions including atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), 
lobular carcinoma in situ (LCIS), low-grade ductal carcinoma in situ (DCIS), and, less 
frequently, low-grade invasive carcinoma.6,13–15 Whether excisional biopsy should be 
offered when FEA is the only risk-associated lesion on core biopsy is not currently 
standardized.16–19 Uncertainty may encourage excisional biopsy.
The surgical outcomes after breast procedures are contingent on the reproducibility and 
accuracy of the pathological diagnosis. However, there is little data evaluating FEA as a 
diagnostic entity within a broad cross-section of practicing pathologists. In this analysis, we 
selected a spectrum of benign breast biopsy cases from the Breast Pathology (B-Path) study. 
Among this large cross-section of U.S. pathologists, we examine variability in diagnosis of 
FEA. We also identify and describe potential challenges associated with establishing a FEA 
diagnosis and the implications for surgical management.
Material and Methods
Data for this study originated from the B-Path Study, a large investigation examining 
diagnostic under- and over-interpretation of breast biopsy specimens by U.S. 
pathologists.20,21 The methods and test sets developed for the B-Path study are described 
elsewhere.22,23 In brief, each of four tests sets (A, B, C, and D) of breast biopsy specimens 
were created after sampling registries in Vermont and New Hampshire associated with the 
Breast Cancer Surveillance Consortium.24 Each test set was composed of 60 cases, one glass 
slide per case, randomized with stratification (N=240) to contain comparable pathological 
findings. Specimens were from excisional and core biopsies and from female patients ≥40 
years of age. All study activities were approved by the Institutional Review Boards at 
Dartmouth College, Fred Hutchinson Cancer Research Center, Providence Health & 
Services Oregon, University of Vermont, and the University of Washington prior to data 
collection.
Reference Diagnosis on Test Cases
A panel of three experienced breast pathologists established a reference consensus 
interpretation for all 240 cases. Blinded to one another’s interpretations, the reference 
pathologists used a Breast Pathology Assessment Tool and Hierarchy for Diagnosis 
(BPATH-Dx) form to independently review each slide before meeting to establish a 
consensus reference diagnosis (Appendix A).25 Pathologists chose 1 or more diagnoses from 
14 BPATH-Dx terms, which were grouped into 4 broad diagnostic categories with the 
following distribution: 30% benign (including normal breast tissue, non-proliferative 
fibrocystic changes, usual ductal hyperplasia [UDH], flat epithelial atypia [FEA], and 
atypical lobular hyperplasia [ALH]); 30% atypia (including atypical ductal hyperplasia 
[ADH] and intraductal papilloma with ADH); 30% DCIS; and 10% invasive carcinoma. 
ALH was included in the benign category exclusively for analytic reasons because lobular 
lesions were not a major focus of the main B-Path study.
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Reference non-FEA Benign and Reference FEA Cases
Following reference consensus interpretation, there were six reference FEA cases that had 
FEA only or a combination of FEA and other lesions categorized as benign according to a 
consensus or majority of reference panel pathologists (Appendix B). FEA was the highest 
category lesion in all six cases. Three reference FEA cases (numbers 1, 2, and 5) were not 
reviewed during the consensus meetings because all three reference panel pathologists 
independently agreed on a benign proliferative diagnosis. In all three cases, two out of three 
reference pathologists (a majority) noted the presence of FEA on their independent 
interpretations. The remaining three reference FEA cases (numbers 3, 4, and 6) did not have 
definitive independent diagnostic agreement and were reviewed at consensus meetings, 
during which all three reference pathologists agreed on the presence of FEA and no higher-
ranking diagnoses. A qualitative analysis of the consensus process for B-Path indicated that 
the most common reason underlying the need for consensus was differing opinions 
regarding whether a particular lesion, such as FEA, met diagnostic criteria.25
There were 72 benign non-FEA reference cases according to the consensus or majority of 
reference panel pathologists. The non-FEA cases comprised a spectrum of benign findings; 
individual slides may have included normal breast tissue, columnar cell change and 
hyperplasia (CCH), UDH, or ALH. Cases where only one reference pathologist indicated the 
presence of FEA were not excluded.
We considered the presence of other diagnoses in case selection because excision of 
proliferative lesions identified on core biopsy is often based on published associations with 
more severe disease on excisional biopsy (i.e., upstaging). For example, surgical excision is 
not routinely recommended for UDH, whereas many centers excise FEA if found on core 
needle biopsy.5,26,27 Excision for ALH on core biopsy is controversial; studies have shown 
that it may pose few risks, or its risk may depend on the extent of its presence.28–34 Thus, 
we included cases of FEA with UDH or ALH. We excluded cases of FEA with coexisting 
higher category lesions, including cases where the reference panel diagnosis noted ADH, 
intraductal papilloma with atypia (IPA), DCIS, or invasive cancer. It is not always standard 
practice for a pathologist to note all diagnostic lesions present on a slide, especially for 
lesions with lower risk relative to the primary diagnosis.
For the global assessment of the proportion of cases in each test set where the study 
participants noted FEA on the diagnostic form, we used all test set cases except those with 
invasive carcinoma. Random stratification of the 240 test cases into 4 test sets resulted in the 
following distribution of reference FEA cases: 3 in test set A, 2 in test set B, and 1 in test set 
C. FEA was not a random stratification variable for creating the test sets.
Participating Pathologist Recruitment and Characteristics
Pathologists with at least one year of experience interpreting breast specimens and who 
planned to continue practicing diagnostic breast pathology for at least one more year were 
recruited from eight states (AK, ME, MN, NH, NM, OR, VT, and WA). Pathology residents 
and fellows were excluded. After providing informed consent, all participants completed a 
web-based survey of demographic information and clinical practice characteristics.
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Participating Pathologist Test Case Interpretation
Participating pathologists were randomly assigned with stratification on clinical expertise to 
independently interpret one of four test sets. Participants received one Hematoxylin and 
Eosin-stained (H&E) glass slide per case. All participants assigned to the same test set 
received the same slides. Pathologists were asked to assess cases and note all of the lesions 
present; there were no study-specific time constraints. Participants completed the same 
BPATH-Dx form for each case online that had been developed and used by the reference 
pathologists. We then determined the proportion of cases where FEA was identified out of 
60 cases (a complete test-set) by each participant, the proportion of cases where FEA was 
identified among the subset of reference non-FEA benign cases, and, finally, the 
participants’ proportional agreement with the six reference FEA cases.
Results
Participating Pathologists’ Characteristics
Of 691 pathologists invited to join the B-Path study, 126 were randomly assigned to interpret 
the glass slide test sets. In total, 91% (115/126) independently interpreted all 60 cases in 
their assigned test set. Most (75.7%) did not have an academic affiliation, 51.3% had 
completed a fellowship in either surgical pathology or breast pathology, 21.7% reported 
being considered experts in breast pathology by their colleagues, and 59.1% worked in 
laboratory practices with fewer than ten pathologists.
Global use of FEA Diagnostic Term by Pathologists for the 60-Case Test Sets
Figure 1 shows the proportion of all test cases where participants and reference pathologists 
noted FEA during their initial independent interpretations. While the majority of 
pathologists noted FEA on 4 or more of the 60 test cases they interpreted, 9 (8%) 
participating pathologists identified FEA in ≥20% of the test cases, and 19 (17%) 
pathologists identified FEA in ≥15% of the cases. The reference pathologists also 
independently differed in the frequency with which they used the FEA diagnostic category 
(<5% to 20% of test cases).
Participating Pathologists’ Assessments of Reference non-FEA Benign Cases
One or more participants noted the presence of FEA on 34 of the 72 reference non-FEA 
benign cases (Table 1). Four of the 34 cases (11.8%) were independently noted to have FEA 
by 1 reference pathologist, even though they did not qualify as reference FEA cases based 
on consensus or the majority of reference pathologists. Six of the 34 cases were noted as 
having FEA by 20% or more of the participating pathologists. Common reference diagnoses 
for these 34 cases included CCH, UDH, and ALH.
Participating Pathologists’ Assessments on the 6 Reference FEA Cases
The study pathologists who interpreted the 6 reference FEA cases provided a total of 175 
individual interpretations (29 to 30 participants interpreted each case). Many participants 
listed multiple lesion types in their interpretations (Appendix B). Pathologists demonstrated 
the highest rate of agreement with the reference FEA diagnosis for case 1 (52%) and the 
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lowest rate of agreement for case 6 (17%). Figure 2 shows common diagnoses by 
participants including CCH, UDH, ADH, and alternative benign lesions.
Discussion
We observed extensive and concerning variability in use of the FEA diagnostic term by 
practicing U.S. pathologists. Some pathologists identified FEA in more than 20% of the 
breast biopsy slides they interpreted, while others refrained from using the FEA term 
entirely. This variability likely represents a combination of differing thresholds for including 
a proliferative lesion in the FEA category, varied understanding or application of diagnostic 
criteria, and the challenge associated with assigning a categorical diagnosis to a continuum 
of histopathological features.
The implications for surgical management of CCH and ADH are generally different than 
those suggested for FEA. A diagnosis of CCH does not warrant further treatment whether 
diagnosed on a core or excisional biopsy, whereas women with ADH are considered at 
increased risk of developing breast cancer and typically undergo excisional biopsy following 
a core biopsy diagnosis to exclude low-grade DCIS. When the final diagnosis is ADH, some 
women consider heightened surveillance and risk reduction using hormonal or surgical 
treatments.35–37 Both ADH and FEA may have adjacent coexisting disease such as low-
grade DCIS and low- grade invasive carcinomas, including tubular carcinomas. For this 
reason, some argue that FEA diagnosed on core biopsy should be followed by excisional 
biopsy to exclude an adjacent low-grade carcinoma. The counter argument is that the 
associated coexisting disease is relatively indolent and could be managed with 
surveillance.8–10,16,17,19 In addition, the intrinsic biologic risk for future breast cancer is 
considerably lower for FEA than for ADH.38
The surgical management of FEA is complicated by the potential magnitude of its 
prevalence in clinical practice. Previous research suggests that up to 10% of all core needle 
breast biopsies may have FEA noted by the interpreting pathologist.2 Our study corroborates 
these observations. Although studies have evaluated the incidence of breast cancer in women 
with FEA,39,40 their applicability relies on the reproducibility of FEA as a diagnostic entity. 
Other studies have found only moderate agreement (Kappa=0.47) for diagnoses of FEA.41
Pathologists with a special interest in breast pathology are better at distinguishing FEA from 
other lesions when tested immediately after a brief educational intervention.42,43 Thus, it is 
possible that the diagnosis of FEA can be improved through education. Figure 3 and Figure 
4 describe some of the educational issues associated with a diagnosis of FEA.
Our study evaluated interpretive variability among a large number of practicing U.S. 
pathologists within a spectrum of cases that were also evaluated by a reference panel. The 
reference panel members also demonstrated substantial variability in their interpretation of 
FEA; however, overall prevalence of FEA decreased following the consensus review process 
that included a discussion of diagnostic criteria. This observation suggests that educational 
interventions may refine understanding of the diagnostic criteria and potentially reduce the 
diagnostic prevalence. Open discussion and communication between radiologists, 
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pathologists, and breast surgeons is perhaps more important than improving pathologist 
reproducibility. Our mutual goal is to segregate lesions associated with future risk of 
developing cancer from lesions associated with current risk for associated aggressive lesions 
that require early intervention and treatment. FEA and its associated family of indolent 
lesions, including ADH, ALH, low-grade DCIS, and small well-differentiated or tubular 
carcinomas are increasingly recognized as lesions that do not pose an immediate threat for 
women participating in breast screening.
Translating test set evaluation to clinical performance has limitations, and the issues 
requiring special consideration are described elsewhere.20,23,25 We also noted a difference 
among participants’ use of the BPATH-Dx form, with most checking multiple boxes, and 
some selecting a single, highest order diagnosis despite being instructed to check all 
applicable diagnostic boxes. We do not know how the order of slides within test sets (which 
was different for each participant), the oversampling of cases with atypia and DCIS, and the 
use of both excisional and core needle biopsies may have affected diagnoses. Participants 
tended to diagnose FEA more often on core biopsies, compared with excisional biopsies; 
however, the sample size was too small to draw any conclusions from this trend.
In summary, our findings show a high degree of variability in the use of FEA as a diagnostic 
entity among practicing U.S. pathologists and suggest that differences between FEA, CCH, 
UDH, and ALH should be discussed in greater detail during clinical case review. Our results 
emphasize the challenges that breast surgeons face when relying on pathologists’ reports and 
stress the need for cross-discipline understanding of diagnostic variability in potentially 
precancerous lesions.
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Appendix A. BPATH-Dx Histology Form for Data Collection on Each Case 
Used by Participating Pathologists. Originally published in K Allison et al 
(2014).19
Appendix B. Participating pathologists’ interpretations of reference FEA 
cases*
Case Number Reference Panel diagnosis** Core or excisional
N 
(Practicing 
Pathologists 
Interpreting 
a case)
Number of 
Pathologists 
who Agree 
with the 
Reference 
Diagnosis 
of FEA
If pathologist does not diagnose the case as FEA, what other diagnosis is given? (%)
Alternative Benign (RS, SA, IPW, FA, ALH, NP)
IPA ADH DCISRS SA IPW FA ALH NP
1 (FEA) Needle Core 29 15 (52%) 7 (24%) 1 (3%) 3(10%) 6(21%)
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Case Number Reference Panel diagnosis** Core or excisional
N 
(Practicing 
Pathologists 
Interpreting 
a case)
Number of 
Pathologists 
who Agree 
with the 
Reference 
Diagnosis 
of FEA
If pathologist does not diagnose the case as FEA, what other diagnosis is given? (%)
Alternative Benign (RS, SA, IPW, FA, ALH, NP)
IPA ADH DCISRS SA IPW FA ALH NP
2 (FEA) Needle Core 29 11 (38%) 20 (69%) 4 (14%) 2 (7%) 1 (3%) 2 (7%) 1 (3%)
3 FEA, CCH Needle Core 29 10 (34%) 17 (59%) 1 (3%) 4 (14%) 1 (3%) 1 (3%)
4 FEA, ALH Excisional 29 8 (28%) 13 (45%) 1 (3%) 2 (7%) 1 (3%) 8 (28%)
5 (UDH, FEA) Excisional 29 7 (24%) 15 (52%) 10(34%) 5 (17%) 5 (17%) 1 (3%) 2 (7%)
6 FEA, UDH, CCH Excisional 30 5 (17%) 11 (37%) 17(57%) 8 (27%) 3 (10%) 1 (3%) 1 (3%) 6(20%)
Diagnostic Category Appreciations: FEA: Flat Epithelial Atypia, CCH: Columnar Cell Hyperplasia, UDH: Usual Ductal 
Hyperplasia, RS: Radial Scar/Complex Sclerosing lesion, SA: Sclerosing Adenosis, IPW: Intraductal Hyperplasia Without 
Atypia, FA: Fibroadenoma, ALH: Atypical Lobular Hyperplasia, NP: Non-Proliferative, ADH: Atypical Ductal 
Hyperplasia, DCIS: Ductal Carcinoma In Situ
*
Percentages add up to >100% because participants could mark combinations of lesion types for a single case
**
Parentheses indicate that the case did not go to consensus. When a case did not got to consensus, the reference diagnosis 
was determined based on which lesions were identified by two or more reference pathologists.
***See Figure 2 for a bar graph of data specified in this appendix B.
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Highlights
• We observed wide variation in the diagnosis of FEA among U.S. pathologists.
• Perceptions of diagnostic criteria and any implied risk for FEA may also vary.
• FEA, CCH, UDH, and ALH should be compared in greater detail during case 
review.
• Surgical excision following core biopsy diagnosis of FEA may not be 
necessary.
• Educational interventions may refine understanding, reduce diagnostic 
variation.
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Fig. 1. 
Percentage of B-Path test set cases interpreted as having FEA present on the glass slide, with 
results shown for each participating pathologist and the three reference pathologists, 
organized according to test seta
a. Each test set was composed of 60 cases. Cases may have been given other higher order 
interpretations along with the diagnosis of FEA. Cases with higher order interpretations and 
cases identified as FEA by only a single reference panel pathologist were not used as 
reference FEA cases.
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Fig. 2. 
Frequency of diagnostic terms used by participating pathologists for reference FEA casesa
a. All six reference FEA cases had FEA only, or a combination of FEA and other lesions 
categorized as benign without atypia according to the reference panel. Percentages add up to 
>100% because participants could mark combinations of lesion types for a single case. See 
Appendix B for a table showing the reference diagnosis for each case and the number of 
participants who interpreted each lesion.
Samples et al. Page 14
Breast. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. Images and discussion points for three cases classified as FEA by reference pathologists
Fig. 3a) Case #1 Focus of FEA with intraluminal secretions. This lesion has round to ovoid 
monomorphic nuclei with some cellular stratification. In areas, the cells are oriented 
perpendicularly to the basement membrane reminiscent of columnar cell change, but in other 
areas, the cells lose this arrangement. Note the lack of slender, bland nuclei typical of 
columnar cell change and the presence of the more rounded nuclear contour of FEA. 2 of the 
3 reference pathologists diagnosed this case as FEA. 52% of participating pathologists 
(N=29) interpreted this as FEA. Hematoxylin and eosin, 400X and 40X
Fig. 3b) Case #3 Focus of FEA in an enlarged TDLU. From low magnification (inset), note 
the dilated, hyperchromatic ducts that raise concern for FEA at scanning magnification. At 
higher magnification, the ducts are filled with rounded monomorphic cells that are not 
regularly oriented perpendicular to the basement membrane. There is cellular stratification 
and, although there are no prominent nucleoli or obvious chromatin margination, the cells 
resemble those seen in low grade ductal carcinoma in-situ. This lesion was interpreted as 
FEA by 34% of participating pathologists (N=29)
Fig. 3c) Case #5 Focus of FEA with prominent apical cytoplasmic snouting. From scanning 
magnification (inset), there are dilated ducts with round contours and hyperchromasia 
Samples et al. Page 15
Breast. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
suggestive of FEA. At higher magnification, although there is no cellular stratification, the 
nuclei are round with a high nuclear to cytoplasmic ratio and prominent chromatin 
margination characteristic of FEA. 2 of the 3 reference pathologists diagnosed this case as 
FEA. This lesion was interpreted as FEA by 24% of participating pathologists (N=29)
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Fig. 4. Images and discussion points for three cases classified as benign or ALH without FEA by 
reference pathologists. These cases were frequently interpreted as FEA by participating 
pathologists
Fig. 4a) Case #7 Focus of columnar cell change and columnar cell hyperplasia in enlarged 
TLDUs with intraluminal calcifications. Although the nuclei of the cells lining the TLDUs 
in this lesion show mild pleomorphism, the cells are arranged perpendicularly to the 
basement membrane and do not have the round to ovoid monomorphic nuclei typical of 
FEA. The nuclear pleomorphism likely results from reaction to the intraluminal 
calcification. This lesion was interpreted as FEA by 67% of participating pathologists 
(N=27). Hematoxylin and eosin, 400X and 40X
Fig. 4b) Case #8 Focus of non-atypical proliferative change with enlarged terminal ductal 
lobular units (TLDUs) with irregular contours and usual ductal hyperplasia. Although from 
low power (see inset), the lesion is hyperchromatic, raising the possibility of FEA, at higher 
power, the cells are cytologically benign and are arranged in a haphazard pattern with poorly 
defined borders characteristic of usual ductal hyperplasia. Note the absence of low grade 
monomorphic round to ovoid nuclei typical of FEA. This lesion was interpreted as FEA by 
37% of participating pathologists (N=30)
Fig. 4c) Case #10 Focus of columnar cell change in enlarged TDLUs. From low 
magnification (inset) the lesion has dilated ducts with round contours and mild 
hyperchromasia that is suggestive of FEA. However, at higher magnification, there is a 
single layer of non-atypical columnar to cuboidal cells with cytoplasmic snouts, intraluminal 
secretions and calcifications. The nuclei are arranged perpendicular to the basement 
membrane with evenly dispersed chromatin and no obvious nucleoli. These are features 
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more consistent with columnar cell change rather than FEA. This lesion was interpreted as 
FEA by 23% of participating pathologists (N=30)
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Table 1
Breast biopsy cases defined as benign with no FEA by the reference consensus panel, yet identified as FEA by 
one or more participating pathologists.
Case Number
FEA was independently 
identified by at least one 
reference panel member Reference panel diagnosisa
Number of Participants who identified FEA/ 
Number of Participants who independently 
interpreted the case (%)
7 Yes (CCH) 18/27 (66.7%)
8 No (UDH, CCH) 11/30 (36.7%)
9 Yes ALH, UDH, CCH 8/30 (26.7%)
10 Yes ALH, UDH, CCH 7/30 (23.3%)
11 Yes UDH 6/29 (20.7%)
12 No Fibroadenoma 6/30 (20.0%)
13 No (UDH, CCH) 5/27 (18.5%)
14 No UDH, CCH 4/27 (14.8%)
15 No (NPR) 4/29 (13.8%)
16 No (CCH) 4/30 (13.3%)
17 No CCH 3/27 (11.1%)
18 No UDH 3/29 (10.3%)
19 No UDH 3/29 (10.3%)
20 No LCIS, IPW, UDH,CCH 3/30 (10.0%)
21 No (UDH, CCH, Fib) 3/30 (10.0%)
22 No (UDH) 2/27 (7.4%)
23 No (UDH) 2/29 (6.9%)
24 No ALH, UDH 2/29 (6.8%)
25 No (UDH, CCH) 2/29 (6.9%)
26 No (CCH, SCL) 2/29 (6.9%)
27 No RSL 2/29 (6.9%)
28 No ALH, UDH, RSL 2/30 (6.7%)
29 No NPR 2/30 (6.7%)
30 No UDH 2/30 (6.7%)
31 No (CCH, RSL, ALH) 1/27 (3.7%)
32 No (UDH) 1/27 (3.7%)
33 No (UDH, CCH) 1/27 (3.7%)
34 No NPR 1/27 (3.7%)
35 No Fibroadenoma 1/27 (3.7%)
36 No UDH 1/29 (3.4%)
37 No (NPR) 1/29 (3.4%)
38 No (NPR) 1/29 (3.4%)
39 No NPR 1/29 (3.4%)
40 No (NPR) 1/30 (3.3%)
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a
Parentheses indicate that the case did not go to consensus. When a case did not go to consensus, the reference diagnosis was determined based on 
which lesions were identified by two or more reference pathologists.
FEA = flat epithelial atypia; CCH = columnar cell change or hyperplasia; UDH = usual ductal hyperplasia; ALH = atypical lobular hyperplasia; 
NPR = non-proliferative changes only; LCIS = lobular carcinoma in situ; IPW = intraductal papilloma without atypia; Fib = fibroadenoma; RSL = 
radial scar/complex sclerosing lesion.
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